GLAXO vs NGLFINE: Stock Comparison
GlaxoSmithKline Pharmaceuticals Limited vs NGL Fine-Chem Limited
Live data: 22 July 2026, 3:05 PM IST • Source: NSE and company filings
GlaxoSmithKline Pharmaceuticals Limited is the larger company by market capitalisation. GlaxoSmithKline Pharmaceuticals Limited shows a lower P/E, a higher ROE and a higher dividend yield, while NGL Fine-Chem Limited shows faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Side-by-side comparison of GlaxoSmithKline Pharmaceuticals Limited and NGL Fine-Chem Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | GLAXO | NGLFINE |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | GLAXO | NGLFINE |
|---|---|---|
| Live Price | ₹2,550.9 | ₹3,260 |
| Day Change | 1.77% | 0.7% |
| Volume | 90,556 | 5,595 |
| 52-Week High | ₹3,220 | ₹3,329 |
| 52-Week Low | ₹2,088.1 | ₹1,175.5 |
| Distance from 52W High | -20.78% | -2.07% |
Valuation
| Metric | GLAXO | NGLFINE |
|---|---|---|
| Market Cap | ₹43,236 Cr | ₹2,015 Cr |
| P/E Ratio | 40.71x | 41.23x |
| P/B Ratio | 18.6x | 6.03x |
| EPS | ₹61.08 | ₹78.04 |
| Book Value | ₹133.85 | ₹532.95 |
| Dividend Yield | 2.3% | 0.05% |
Growth
| Metric | GLAXO | NGLFINE |
|---|---|---|
| Revenue Growth (TTM YoY) | 2.1% | 57.2% |
| EPS Growth (TTM YoY) | 5.7% | 1,539.8% |
| Qtr Sales Growth | 2.15% | 57.1% |
| Qtr Profit Growth | 5.7% | 2,398% |
Profitability & Leverage
| Metric | GLAXO | NGLFINE |
|---|---|---|
| ROE | 45.6% | 15.7% |
| ROCE | 61.4% | 17% |
| Net Margin | 27.29% | 9.59% |
| Operating Margin | 34.3% | 14.5% |
| Debt to Equity | 0.01x | 0.33x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | GLAXO | NGLFINE |
|---|---|---|
| Promoter Holding | 75% | 72.74% |
| FII Holding | 4.79%▲ 0.17 pp | 0.03%▲ 0.03 pp |
| DII Holding | 7.8%▲ 0.12 pp | 0% |
| Public Holding | 12.41%▼ 0.28 pp | 27.24%▼ 0.02 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: GlaxoSmithKline Pharmaceuticals Limited and NGL Fine-Chem Limited.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.